Amedeo Smart

Free Medical Literature Service




  Free Subscription

Articles published in
    September 2022
  1. LI L, Li Y, Bai Y, Li G, et al
    Neutralizing antibody activity, safety and immunogenicity of human anti-rabies virus monoclonal antibody (Ormutivimab) in Chinese healthy adults: A phase b randomized, double-blind, parallel-controlled study.
    Vaccine. 2022 Sep 16. pii: S0264-410X(22)01114.
    >> Share

    August 2022
  2. QUIAMBAO BP, Lim JG, Bosch Castells V, Augard C, et al
    One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell vaccine or Vero cell rabies vaccine, followed by simulated post-exposure prophylaxis at one year: A phase III, open-label, randomized, controlled trial to assess im
    Vaccine. 2022 Aug 3. pii: S0264-410X(22)00923.
    >> Share

    July 2022
  3. QUIAMBAO B, Montalban C, Minutello AM, Guinet-Morlot F, et al
    Serum-free purified Vero rabies vaccine is safe and immunogenic in children: Results of a randomized phaseII pre-exposure prophylaxis regimen study.
    Vaccine. 2022 Jul 26. pii: S0264-410X(22)00830.
    >> Share

    June 2022
  4. PICHON S, Moureau A, Petit C, Chu L, et al
    Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: A randomised phase II pre-exposure prophylaxis study.
    Vaccine. 2022 Jun 28. pii: S0264-410X(22)00806.
    >> Share

  5. WANG L, Zhang J, Meng S, Ge L, et al
    Safety and immunogenicity of human rabies vaccine for the Chinese population after PEP: A systematic review and meta-analysis.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00784.
    >> Share

    November 2021
  6. YE K, Shi D, Zhang Z, Bian L, et al
    A chemiluminescence immunoassay for precise automatic quality control of glycoprotein in human rabies vaccine.
    Vaccine. 2021 Nov 20. pii: S0264-410X(21)01393.
    >> Share

    September 2021
  7. MCCLAIN JB, Chuang A, Reid C, Moore SM, et al
    Rabies virus neutralizing activity, pharmacokinetics, and safety of the monoclonal antibody mixture SYN023 in combination with rabies vaccination: Results of a phase 2, randomized, blinded, controlled trial.
    Vaccine. 2021 Sep 2. pii: S0264-410X(21)01114.
    >> Share

    June 2021
  8. ODITA CI, Conan A, Smith-Antony M, Battice J, et al
    Non-specific effects of rabies vaccine on the incidence of self-reported common infectious disease episodes: A randomized controlled trial.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00719.
    >> Share

  9. ITO N, Okamoto T, Sasaki M, Miyamoto S, et al
    Safety enhancement of a genetically modified live rabies vaccine strain by introducing an attenuating Leu residue at position 333 in the glycoprotein.
    Vaccine. 2021 Jun 3. pii: S0264-410X(21)00553.
    >> Share

    April 2021
  10. JENSEN KJ, Tolstrup LK, Knobel DL, Aaby P, et al
    Non-specific effects of maternal and offspring rabies vaccination on mortality and antibiotic use in a Danish pig herd: A randomized trial.
    Vaccine. 2021 Apr 9. pii: S0264-410X(21)00399.
    >> Share

  11. SMITH TG, Fooks AR, Moore SM, Freuling CM, et al
    Negligible risk of rabies importation in dogs thirty days after demonstration of adequate serum antibody titer.
    Vaccine. 2021 Apr 4. pii: S0264-410X(21)00368.
    >> Share

    January 2021
  12. KNOBEL DL, Arega SM, Conan A
    Sex-differential non-specific effects of rabies vaccine in dogs: An extended analysis of a randomized controlled trial in a high-mortality population.
    Vaccine. 2021 Jan 22. pii: S0264-410X(21)00045.
    >> Share

  13. ALDRICH C, Leroux-Roels I, Huang KB, Bica MA, et al
    Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial.
    Vaccine. 2021 Jan 21. pii: S0264-410X(20)31667.
    >> Share

  14. XU C, Lau CL, Clark J, Rafferty AC, et al
    Immunogenicity after pre- and post-exposure rabies vaccination: A systematic review and dose-response meta-analysis.
    Vaccine. 2021 Jan 18. pii: S0264-410X(21)00039.
    >> Share

    July 2020
  15. TROTTER C, Abela-Ridder B, Bharti O, Knopf L, et al
    Reply to 'Alternative abridged preventive regimens against rabies for children in high endemic countries'.
    Vaccine. 2020;38:5580-5581.
    >> Share

  16. SOENTJENS P, Van Damme P, Bottieau E
    'Alternative abridged preventive regimens against rabies for children in high endemic countries'.
    Vaccine. 2020;38:5578-5579.
    >> Share

    June 2020
  17. UNDURRAGA EA, Millien MF, Allel K, Etheart MD, et al
    Costs and effectiveness of alternative dog vaccination strategies to improve dog population coverage in rural and urban settings during a rabies outbreak.
    Vaccine. 2020 Jun 29. pii: S0264-410X(20)30767.
    >> Share

  18. PARIZE P, Poujol P, Morineau Le Houssine P, Goesch J, et al
    Immune response to rabies post-exposure prophylaxis in patients with non-HIV secondary immunodeficiencies.
    Vaccine. 2020 Jun 22. pii: S0264-410X(20)30823.
    >> Share

  19. ANGSUWATCHARAKON P, Ratananpinit N, Yoksan S, Saengseesom W, et al
    Immunogenicity and safety of two-visit, intradermal pre-exposure rabies prophylaxis simultaneously administrated with chimeric live-attenuated Japanese encephalitis vaccine in children living in rabies and Japanese encephalitis endemic country.
    Vaccine. 2020 Jun 7. pii: S0264-410X(20)30699.
    >> Share

  20. BONWITT J, Bonaparte S, Blanton J, Gibson AD, et al
    Oral bait preferences and feasibility of oral rabies vaccination in Bangladeshi dogs.
    Vaccine. 2020 Jun 5. pii: S0264-410X(20)30692.
    >> Share

    May 2020
  21. MORGENROTH A, Jakel V, Hanke-Robinson H, Muller T, et al
    A novel electrophoretic immunoblot as antigen desorption and quantification method for alum-adjuvanted veterinary rabies vaccines.
    Vaccine. 2020 May 8. pii: S0264-410X(20)30561.
    >> Share

  22. QUIAMBAO BP, Ambas C, Diego S, Bosch Castells V, et al
    Single-visit, 4-site intradermal (ID) rabies vaccination induces robust immune responses 5 years after 1-week, 4-site ID primary post-exposure prophylaxis in the Philippines.
    Vaccine. 2020;38:3740-3746.
    >> Share

    September 2019
  23. LUO J, Zhang Y, He H, Liu Q, et al
    Artesunate enhances the immune response of rabies vaccine as an adjuvant.
    Vaccine. 2019 Sep 30. pii: S0264-410X(19)31305.
    >> Share

    August 2019
  24. SREENIVASAN N, Li A, Shiferaw M, Tran CH, et al
    Overview of rabies post-exposure prophylaxis access, procurement and distribution in selected countries in Asia and Africa, 2017-2018.
    Vaccine. 2019 Aug 27. pii: S0264-410X(19)30475.
    >> Share

  25. ZHAO R, Yu P, Shan Y, Thirumeni N, et al
    Rabies virus glycoprotein serology ELISA for measurement of neutralizing antibodies in sera of vaccinated human subjects.
    Vaccine. 2019 Aug 27. pii: S0264-410X(19)31107.
    >> Share

  26. BHARTI OK, Thakur B, Rao R
    Wound-only injection of rabies immunoglobulin (RIG) saves lives and costs less than a dollar per patient by "pooling strategy".
    Vaccine. 2019 Aug 5. pii: S0264-410X(19)31008.
    >> Share

    July 2019
  27. JANEWONGWIROT P, Jantarabenjakul W, Anugulruengkitt S, Anunsittichai O, et al
    A randomized open-label trial of 2-dose or 3-dose pre-exposure rabies prophylaxis among Thai children.
    Vaccine. 2019 Jul 26. pii: S0264-410X(19)30953.
    >> Share

  28. WAMBURA G, Mwatondo A, Muturi M, Nasimiyu C, et al
    Rabies vaccine and immunoglobulin supply and logistics: Challenges and opportunities for rabies elimination in Kenya.
    Vaccine. 2019 Jul 17. pii: S0264-410X(19)30659.
    >> Share

  29. TRABELSI K, Ben Zakour M, Kallel H
    Purification of rabies virus produced in Vero cells grown in serum free medium.
    Vaccine. 2019 Jul 9. pii: S0264-410X(19)30849.
    >> Share

    June 2019
  30. SOBEY KG, Jamieson SE, Walpole AA, Rosatte RC, et al
    ONRAB(R) oral rabies vaccine is shed from, but does not persist in, captive mammals.
    Vaccine. 2019 Jun 24. pii: S0264-410X(19)30808.
    >> Share

  31. GUO Z, Bai L, Gong S
    Some comments on the scandal of rabies vaccine in China.
    Vaccine. 2019 Jun 13. pii: S0264-410X(19)30732.
    >> Share

  32. ROUROU S, Ben Zakkour M, Kallel H
    Adaptation of Vero cells to suspension growth for rabies virus production in different serum free media.
    Vaccine. 2019 Jun 11. pii: S0264-410X(19)30749.
    >> Share

    May 2019
  33. FORRO B, Marton S, Kecskemeti S, Hornyak A, et al
    Vaccine-associated rabies in red fox, Hungary.
    Vaccine. 2019 May 17. pii: S0264-410X(19)30628.
    >> Share

    March 2019
  34. WENTWORTH D, Hampson K, Thumbi SM, Mwatondo A, et al
    A social justice perspective on access to human rabies vaccines.
    Vaccine. 2019 Mar 27. pii: S0264-410X(19)30150.
    >> Share

  35. TAYLOR E, Banyard AC, Bourhy H, Cliquet F, et al
    Avoiding preventable deaths: The scourge of counterfeit rabies vaccines.
    Vaccine. 2019 Mar 25. pii: S0264-410X(19)30369.
    >> Share

  36. QUIAMBAO BP, Ambas C, Diego S, Bosch Castells V, et al
    Intradermal post-exposure rabies vaccination with purified Vero cell rabies vaccine: Comparison of a one-week, 4-site regimen versus updated Thai Red Cross regimen in a randomized non-inferiority trial in the Philippines.
    Vaccine. 2019 Mar 16. pii: S0264-410X(19)30335.
    >> Share

  37. CHEN T, Zhou X, Qi Y, Mi L, et al
    Feline herpesvirus vectored-rabies vaccine in cats: A dual protection.
    Vaccine. 2019 Mar 13. pii: S0264-410X(19)30310.
    >> Share

    February 2019
  38. DOENER F, Hong HS, Meyer I, Tadjalli-Mehr K, et al
    RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial.
    Vaccine. 2019 Feb 21. pii: S0264-410X(19)30219.
    >> Share

  39. KESSELS J, Tarantola A, Salahuddin N, Blumberg L, et al
    Rabies post-exposure prophylaxis: A systematic review on abridged vaccination schedules and the effect of changing administration routes during a single course.
    Vaccine. 2019 Feb 5. pii: S0264-410X(19)30105.
    >> Share

  40. TRAN CH, Afriyie DO, Pham TN, Otsu S, et al
    Rabies post-exposure prophylaxis initiation and adherence among patients in Vietnam, 2014-2016.
    Vaccine. 2019 Feb 2. pii: S0264-410X(19)30093.
    >> Share

    January 2019
    Rabies post-exposure vaccination in 2 visits within a week: A 4-site intradermal regimen.
    Vaccine. 2019 Jan 25. pii: S0264-410X(19)30073.
    >> Share

  42. RUPPRECHT CE, Kuzmin IV, Yale G, Nagarajan T, et al
    Priorities in applied research to ensure programmatic success in the global elimination of canine rabies.
    Vaccine. 2019 Jan 23. pii: S0264-410X(19)30068.
    >> Share

    December 2018
  43. RYSAVA K, Miranda ME, Zapatos R, Lapiz S, et al
    On the path to rabies elimination: The need for risk assessments to improve administration of post-exposure prophylaxis.
    Vaccine. 2018 Dec 17. pii: S0264-410X(18)31627.
    >> Share

  44. ANOTHAISINTAWEE T, Julienne Genuino A, Thavorncharoensap M, Youngkong S, et al
    Cost-effectiveness modelling studies of all preventive measures against rabies: A systematic review.
    Vaccine. 2018 Dec 13. pii: S0264-410X(18)31634.
    >> Share

  45. DENIS M, Knezevic I, Wilde H, Hemachudha T, et al
    An overview of the immunogenicity and effectiveness of current human rabies vaccines administered by intradermal route.
    Vaccine. 2018 Dec 11. pii: S0264-410X(18)31635.
    >> Share

  46. HAMPSON K, Abela-Ridder B, Bharti O, Knopf L, et al
    Modelling to inform prophylaxis regimens to prevent human rabies.
    Vaccine. 2018 Dec 7. pii: S0264-410X(18)31519.
    >> Share

  47. RATTANAVIPAPONG W, Thavorncharoensap M, Youngkong S, Genuino AJ, et al
    The impact of transmission dynamics of rabies control: Systematic review.
    Vaccine. 2018 Dec 5. pii: S0264-410X(18)31558.
    >> Share

    November 2018
  48. RAJEEV M, Edosoa G, Hanitriniaina C, Andriamandimby SF, et al
    Healthcare utilization, provisioning of post-exposure prophylaxis, and estimation of human rabies burden in Madagascar.
    Vaccine. 2018 Nov 30. pii: S0264-410X(18)31520.
    >> Share

  49. SPARROW E, Torvaldsen S, Newall AT, Wood JG, et al
    Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline.
    Vaccine. 2018 Nov 29. pii: S0264-410X(18)31503.
    >> Share

  50. TARANTOLA A, Tejiokem MC, Briggs DJ
    Evaluating new rabies post-exposure prophylaxis (PEP) regimens or vaccines.
    Vaccine. 2018 Nov 21. pii: S0264-410X(18)31542.
    >> Share

  51. TARANTOLA A, Ly S, Chan M, In S, et al
    Intradermal rabies post-exposure prophylaxis can be abridged with no measurable impact on clinical outcome in Cambodia, 2003-2014.
    Vaccine. 2018 Nov 16. pii: S0264-410X(18)31420.
    >> Share

  52. IVES A, Dieuzy-Labaye I, Abela-Ridder B
    Global characteristics of the rabies biologics market in 2017.
    Vaccine. 2018 Nov 9. pii: S0264-410X(18)31364.
    >> Share

    October 2018
  53. O'BRIEN KL, Nolan T
    The WHO position on rabies immunization - 2018 updates.
    Vaccine. 2018 Oct 17. pii: S0264-410X(18)31366.
    >> Share

  54. LI AJ, Sreenivasan N, Siddiqi UR, Tahmina S, et al
    Descriptive assessment of rabies post-exposure prophylaxis procurement, distribution, monitoring, and reporting in four Asian countries: Bangladesh, Bhutan, Cambodia, and Sri Lanka, 2017-2018.
    Vaccine. 2018 Oct 9. pii: S0264-410X(18)31363.
    >> Share

  55. CHANGALUCHA J, Steenson R, Grieve E, Cleaveland S, et al
    The need to improve access to rabies post-exposure vaccines: Lessons from Tanzania.
    Vaccine. 2018 Oct 8. pii: S0264-410X(18)31243.
    >> Share

    August 2018
  56. FOOKS AR, Banyard AC, Ertl HCJ
    New human rabies vaccines in the pipeline.
    Vaccine. 2018 Aug 25. pii: S0264-410X(18)31168.
    >> Share

  57. GONGAL G, Sampath G
    Introduction of intradermal rabies vaccination - A paradigm shift in improving post-exposure prophylaxis in Asia.
    Vaccine. 2018 Aug 24. pii: S0264-410X(18)31163.
    >> Share

    Rabies vaccines: WHO position paper, April 2018 - Recommendations.
    Vaccine. 2018 Aug 11. pii: S0264-410X(18)30902.
    >> Share

  59. SHI W, Kou Y, Xiao J, Zhang L, et al
    Comparison of immunogenicity, efficacy and transcriptome changes of inactivated rabies virus vaccine with different adjuvants.
    Vaccine. 2018;36:5020-5029.
    >> Share

  60. GILBERT A, Johnson S, Walker N, Wickham C, et al
    Efficacy of Ontario Rabies Vaccine Baits (ONRAB) against rabies infection in raccoons.
    Vaccine. 2018;36.
    >> Share

    June 2018
  61. HOENIG LJ, Jackson AC, Dickinson GM
    The early use of Pasteur's rabies vaccine in the United States.
    Vaccine. 2018 Jun 16. pii: S0264-410X(18)30623.
    >> Share

    May 2018
  62. MARTINA BEE, Smreczak M, Orlowska A, Marzec A, et al
    Combination drug treatment prolongs survival of experimentally infected mice with silver-haired bat rabies virus.
    Vaccine. 2018 May 26. pii: S0264-410X(18)30705.
    >> Share

  63. MAROSI A, Dufkova L, Forro B, Felde O, et al
    Combination therapy of rabies-infected mice with inhibitors of pro-inflammatory host response, antiviral compounds and human rabies immunoglobulin.
    Vaccine. 2018 May 24. pii: S0264-410X(18)30706.
    >> Share

    April 2018
  64. KORAKA P, Martina BEE, Smreczak M, Orlowska A, et al
    Inhibition of caspase-1 prolongs survival of mice infected with rabies virus.
    Vaccine. 2018 Apr 10. pii: S0264-410X(18)30470.
    >> Share

  65. SMRECZAK M, Orlowska A, Marzec A, Trebas P, et al
    The effect of combined drugs therapy on the course of clinical rabies infection in a murine model.
    Vaccine. 2018 Apr 9. pii: S0264-410X(18)30471.
    >> Share

    March 2018
  66. CLEATON JM, Wallace RM, Crowdis K, Gibson A, et al
    Impact of community-delivered SMS alerts on dog-owner participation during a mass rabies vaccination campaign, Haiti 2017.
    Vaccine. 2018 Mar 23. pii: S0264-410X(18)30353.
    >> Share

  67. PHOOLCHAROEN W, Banyard AC, Prehaud C, Selden D, et al
    In vitro and in vivo evaluation of a single chain antibody fragment generated in planta with potent rabies neutralisation activity.
    Vaccine. 2018 Mar 6. pii: S0264-410X(18)30244.
    >> Share

    February 2018
  68. MAROSI A, Forgach P, Gyuranecz M, Sulyok KM, et al
    Evaluation of in vitro inhibitory potential of type-I interferons and different antiviral compounds on rabies virus replication.
    Vaccine. 2018 Feb 16. pii: S0264-410X(18)30155.
    >> Share

  69. PFAFF F, Muller T, Freuling CM, Fehlner-Gardiner C, et al
    In-depth genome analyses of viruses from vaccine-derived rabies cases and corresponding live-attenuated oral rabies vaccines.
    Vaccine. 2018 Feb 10. pii: S0264-410X(18)30156.
    >> Share

    January 2018
  70. VOS A, Freuling C, Ortmann S, Kretzschmar A, et al
    An assessment of shedding with the oral rabies virus vaccine strain SPBN GASGAS in target and non-target species.
    Vaccine. 2018 Jan 8. pii: S0264-410X(17)31839.
    >> Share

    December 2017
  71. JOCHMANS D, Neyts J
    The path towards effective antivirals against rabies.
    Vaccine. 2017 Dec 23. pii: S0264-410X(17)31812.
    >> Share

  72. DUFKOVA L, Sirmarova J, Salat J, Honig V, et al
    Mannitol treatment is not effective in therapy of rabies virus infection in mice.
    Vaccine. 2017 Dec 20. pii: S0264-410X(17)31781.
    >> Share

    November 2017
  73. GALVEZ-ROMERO G, Salas-Rojas M, Pompa-Mera EN, Chavez-Rueda K, et al
    Addition of C3d-P28 adjuvant to a rabies DNA vaccine encoding the G5 linear epitope enhances the humoral immune response and confers protection.
    Vaccine. 2017 Nov 27. pii: S0264-410X(17)31611.
    >> Share

  74. SIRIKUN J, Suputtamongkol Y, Rattanachinakorn P, Primsirikunawut A, et al
    Immunogenic response in obese patients undergoing rabies post-exposure prophylaxis with combined equine rabies immunoglobulin and rabies vaccination.
    Vaccine. 2017 Nov 27. pii: S0264-410X(17)31622.
    >> Share

  75. KALIMUDDIN S, Wijaya L, Chan YFZ, Wong AWL, et al
    A phase II randomized study to determine the safety and immunogenicity of the novel PIKA rabies vaccine containing the PIKA adjuvant using an accelerated regimen.
    Vaccine. 2017 Nov 21. pii: S0264-410X(17)31526.
    >> Share

  76. SMRECZAK M, Marzec A, Orlowska A, Trebas P, et al
    The effect of selected molecules influencing the detrimental host immune response on a course of rabies virus infection in a murine model.
    Vaccine. 2017 Nov 15. pii: S0264-410X(17)31527.
    >> Share

  77. BAGHI HB, Bazmani A, Aghazadeh M
    Canine vaccination: Bridging the rabies knowledge gap.
    Vaccine. 2017 Nov 15. pii: S0264-410X(17)31575.
    >> Share

  78. BANYARD AC, Mansfield KL, Wu G, Selden D, et al
    Re-evaluating the effect of Favipiravir treatment on rabies virus infection.
    Vaccine. 2017 Nov 10. pii: S0264-410X(17)31541.
    >> Share

    October 2017
  79. WERA E, Mourits MCM, Hogeveen H
    Cost-effectiveness of mass dog rabies vaccination strategies to reduce human health burden in Flores Island, Indonesia.
    Vaccine. 2017 Oct 24. pii: S0264-410X(17)31374.
    >> Share

  80. LEGER A, De Nardi M, Simons R, Adkin A, et al
    Assessment of biosecurity and control measures to prevent incursion and to limit spread of emerging transboundary animal diseases in Europe: An expert survey.
    Vaccine. 2017;35:5956-5966.
    >> Share

  81. SMITH TG, Millien M, Vos A, Fracciterne FA, et al
    Evaluation of immune responses in dogs to oral rabies vaccine under field conditions.
    Vaccine. 2017 Oct 17. pii: S0264-410X(17)31388.
    >> Share

  82. FREULING CM, Eggerbauer E, Finke S, Kaiser C, et al
    Efficacy of the oral rabies virus vaccine strain SPBN GASGAS in foxes and raccoon dogs.
    Vaccine. 2017 Oct 14. pii: S0264-410X(17)31366.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016